Halozyme Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGHalozyme Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 76), indicating performance broadly in line with the market. Earnings growth of 31% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $73.13 | +11.54% | ABOVE |
| 50 SMA | $69.56 | +17.26% | ABOVE |
| 100 SMA | $68.62 | +18.87% | ABOVE |
| 150 SMA | $69.06 | +18.12% | ABOVE |
| 200 SMA | $69.16 | +17.94% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is HALO in an uptrend right now?
HALO has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is HALO overbought or oversold?
HALO's RSI (14) is 74. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is HALO outperforming the market?
HALO has a Relative Strength (RS) Rating of 76 out of 99. HALO is performing about average compared to the market.
Where is HALO in its 52-week range?
HALO is trading at $81.57, which is 99% of its 52-week high ($82.26) and 98% above its 52-week low ($54.15).
How volatile is HALO?
HALO has a Beta of 0.59 and 52-week volatility of 31%. It's less volatile than the S&P 500 - generally more stable.